NCT00130637View on ClinicalTrials.gov

Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Anterior UveitisArthritis, Juvenile IdiopathicIritisImmunosuppression
Interventions
DRUG

Daclizumab

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
collaborator

The Emmes Company, LLC

INDUSTRY

lead

National Eye Institute (NEI)

NIH

NCT00130637 - Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis | Biotech Hunter | Biotech Hunter